{"id":6984,"date":"2026-04-25T06:47:34","date_gmt":"2026-04-25T04:47:34","guid":{"rendered":"https:\/\/mediconomics.com\/?post_type=glossary&p=6984"},"modified":"2026-07-13T19:09:41","modified_gmt":"2026-07-13T17:09:41","slug":"endpoint-adjudication","status":"publish","type":"glossary","link":"https:\/\/mediconomics.com\/en\/glossar\/endpoint-adjudication\/","title":{"rendered":"Endpoint Adjudication"},"content":{"rendered":"

Endpoint Adjudication<\/strong> refers to a structured, usually blinded process used to assess and classify critical clinical endpoints uniformly according to predefined criteria. The aim is to reduce misclassification and inter-site differences, thereby increasing data quality and the interpretability of efficacy and safety results.<\/p>\n

When Endpoint Adjudication is used<\/h2>\n

The process is typically used in trials where endpoints are complex, require clinical interpretation, or carry an increased risk of subjective assessment. Common use cases include cardiovascular events (e.g. myocardial infarction, stroke), oncological progression events, hospitalisations or certain safety events.<\/p>\n

In multinational and multicentre trials, Endpoint Adjudication is particularly relevant because diagnostics, documentation practice and clinical thresholds can vary by site. A central, standardised assessment methodologically mitigates these effects.<\/p>\n

Distinction from similar concepts<\/h2>\n

Endpoint Adjudication should not be equated with central monitoring: while monitoring addresses data verification and process quality, adjudication focuses on the medical-content definition and assignment of the endpoint. Adjudication also differs from source data verification, in which primary documents are compared with data documented in the eCRF; in adjudication, the focus is on clinical plausibility and criteria assessment.<\/p>\n

For some trials, a blinded assessment by an independent committee is additionally established (e.g. a “blinded endpoint committee”). Endpoint Adjudication can be understood as a specific process within such a committee structure.<\/p>\n

Typical process and roles (sponsor, CRO, investigational sites)<\/h2>\n

The process begins with defining the endpoints relevant for adjudication in the clinical study protocol and in associated work instructions. During the trial, investigational sites report potential endpoint cases (often as a “suspected endpoint”), including defined source documents (findings, discharge letters, imaging, laboratory values). These documents are collected in a controlled workflow, pseudonymised where necessary, and forwarded to the adjudication system or the reviewers.<\/p>\n

In practice, the operational conduct is often organised by a CRO: case intake, completeness checks, query management, scheduling of reviewers, documentation of decisions, and feeding back the final adjudicated classification into the study database. The sponsor is responsible for governance, independence and the contractual framework (including reviewer qualification).<\/p>\n

To minimise bias, the assessment is conducted, wherever possible, blinded to treatment allocation and, where appropriate, to certain course-of-disease criteria. In the event of discrepancies between reviewers, escalation levels are customary (e.g. a third reviewer or a consensus meeting).<\/p>\n

Data management and quality aspects<\/h2>\n

Endpoint Adjudication has direct interfaces with clinical data management: unique case IDs, defined data interfaces, audit trail, versioning of criteria, and a clear separation between the raw report and the adjudicated outcome. It is important that adjudication decisions are traceably documented and integrated into the database without overwriting primary data.<\/p>\n

Typical quality risks include incomplete documents, inconsistent terminology, delayed case reporting, or inconsistent application of the criteria. A practice-proven approach is a detailed adjudication charter with a decision tree, examples and edge cases, as well as training and calibration rounds for reviewers before study start.<\/p>\n

Regulatory and methodological classification<\/h2>\n

Regulatorily, Endpoint Adjudication is not an end in itself but an instrument for safeguarding the validity of endpoints.<\/p>\n

From a statistical perspective, independent endpoint assessment can stabilise the event definition and thereby improve the power and interpretability of analyses, particularly for endpoints with “soft” diagnostic criteria. At the same time, the process must be transparently reflected in the analysis: it should be clear whether the adjudicated classification is used as the primary basis and how discrepancies between the site report and the adjudication decision are handled (e.g. via sensitivity analyses).<\/p>\n

Operationally, early coordination between clinical operations, medical monitoring, data management and statistics is recommended, in order to define deadlines, cut-offs and data flows such that adjudication does not become a “bottleneck”. Typical control metrics are case turnaround time, the proportion of incomplete dossiers, and the consensus rate between reviewers; these metrics can be used in ongoing quality management.<\/p>\n

Regulatorily, Endpoint Adjudication is not an end in itself but an instrument for safeguarding the validity of endpoints. In Europe, Regulation (EU) 536\/2014 (Clinical Trials Regulation) is particularly relevant for medicinal product trials, as it emphasises requirements for quality, data integrity and traceability of clinical study data. In addition, the principles of Good Clinical Practice (ICH E6(R3), currently being implemented) are decisive, particularly with regard to roles, documentation, quality management and auditability.<\/p>\n

For medical devices, the EU MDR 2017\/745 can be relevant in appropriate settings, for example where clinical data contribute to the clinical evaluation. In all cases: adjudication must be provided for in the protocol and in the statistical analyses, so that the analysis (e.g. time-to-event analyses) is based on consistent endpoint definitions.<\/p>\n

FAQ<\/h2>\n

Why is the investigator’s assessment at the site not sufficient?<\/h3>\n

Investigational sites are essential for clinical assessment, but they operate under differing conditions and may be subject to unconscious differences in interpretation. Central adjudication ensures uniform application of criteria and reduces site-related variance.<\/p>\n

Must Endpoint Adjudication always be blinded?<\/h3>\n

Blinding is advisable in many cases because it reduces the risk of systematic bias. Whether it is strictly required depends on the type of endpoint, study design and operational feasibility, and should be justified in the study protocol.<\/p>\n

Which documents are typically required for adjudication?<\/h3>\n

This depends on the endpoint. Common documents include diagnostic reports (e.g. imaging, ECG), laboratory values, physician letters, surgical reports, medication lists and relevant time points. A clearly defined document set in the adjudication charter prevents follow-up requests and delays.<\/p>\n

Regulatory references (selection):<\/strong> Regulation (EU) 536\/2014 (Clinical Trials Regulation); ICH E6(R3) Good Clinical Practice; EU MDR 2017\/745.<\/p>\n","protected":false},"excerpt":{"rendered":"

Endpoint Adjudication refers to a structured, usually blinded process used to assess and classify critical clinical endpoints uniformly according to predefined criteria. The aim is to reduce misclassification and inter-site differences, thereby increasing data quality and the interpretability of efficacy and safety results. When Endpoint Adjudication is used The process is typically used in trials […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6984","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6984\/revisions"}],"predecessor-version":[{"id":6987,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6984\/revisions\/6987"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6984"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}